ADVANCES IN CANCER NANOTECHNOLOGY: NCI ALLIANCE 2005-2010 The NCI Office of Cancer Nanotechnology Research/ Center for Strategic Scientific Initiatives National Cancer Institute/ NIH NOVEMBER 2010 NCI Alliance for Nanotechnology in Cancer NCI Alliance for Nanotechnology in Cancer TABLE OF CONTENTS ABOUT THE ALLIANCE FOR NANOTECHNOLOGY IN CANCER ............................................ 3 SCIENTIFIC FOCUS ............................................................................................................................................................... 4 PROGRAM OPERATION AND STRUCTURE .......................................................................... 7 PROGRAM OPERATION ........................................................................................................................................................... 7 Office of Cancer Nanotechnology Research ....................................................................................................................... 8 PROGRAM INFRASTRUCTURE ..................................................................................................................................................... 8 Centers of Cancer Nanotechnology Excellence ................................................................................................................. 9 Cancer Nanotechnology Platform Partnerships .............................................................................................................. 11 Multidisciplinary Research Training and Team Development ....................................................................................... 16 Nanotechnology Characterization Laboratory ................................................................................................................ 17 SCIENTIFIC ACHIEVEMENTS ............................................................................................. 19 RECOGNITION AWARDS .......................................................................................................................................................... 19 SCIENTIFIC HIGHLIGHTS ......................................................................................................................................................... 21 MOLECULAR IMAGING AND THE EARLY DETECTION OF CANCER ................................................................................................. 21 Magneto-Nano Protein Chip and Multiplex Sorter for Monitoring Tumors Antigens .................................................. 21 Biobarcode Assay for Measuring Undetectable Levels of Prostate Specific Antigen ....................................................... 25 IN VIVO IMAGING .................................................................................................................................................................... 27 Tumor Cell Imaging Using Magnetic Nanoparticles ..................................................................................................... 27 Near-Infrared Fluorescent Nanoparticles for Targeted Optical Imaging and Drug Delivery......................................... 28 REPORTERS OF THERAPEUTIC EFFICACY .................................................................................................................................. 30 Targeted Nanosystems for Therapy and Imaging ........................................................................................................... 30 Implantable Device for Continuous Cancer Monitoring................................................................................................. 32 Blood Protein Profiling of Glioblastoma Patients: Addressing the Question of Patient Response to Avastin® Therapy 32 MULTIFUNCTIONAL THERAPEUTICS ......................................................................................................................................... 34 Nanotherapeutic Strategy for Multidrug Resistant Tumors .......................................................................................... 34 Dendrimer Nanoparticles for Cancer Diagnosis and Treatment .................................................................................... 35 Targeting Central Nervous System Tumors with Imaging Nanoprobes ........................................................................ 36 Multifunctional Nanoparticles for Early Detection of Pancreatic Cancer ...................................................................... 37 PREVENTION AND CONTROL OF CANCER .................................................................................................................................. 38 PRINT® Technology for Cancer Therapy and Imaging .................................................................................................. 38 Rapid Isolation and Detection of Cell Free Circulating DNA Biomarkers and Nanoparticles Directly from Whole Blood .............................................................................................................................................................. 39 RESEARCH ENABLERS ............................................................................................................................................................. 40 Deconstructing Directional Cell Motility in Metastasis through Nanopatterning ........................................................ 40 Cancer Antibody Functionalized Gold Nanopyramids ................................................................................................... 41 Diagnostic Nanoarrays ................................................................................................................................................... 42 PUBLICATION STATISTICS ....................................................................................................................................................... 42 Selected Publications with High Impact Factor .............................................................................................................. 43 DEVELOPMENT OF TRANSLATIONAL TECHNOLOGIES .................................................... 45 MOVING TO THE CLINIC .......................................................................................................................................................... 45 Cyclodextrin for Delivering Camptothecin and siRNA .................................................................................................. 45 New PET Imaging Agent ............................................................................................................................................... 47 Novel Nanotechnology-Based MRI Contrast Agent ....................................................................................................... 48 Superparamagnetic Nanoparticles for Detection Lymph Node Metastases .................................................................... 49 Polymeric Nanoparticles for Targeted Anticancer Drug Delivery ................................................................................. 50 NCI Alliance for Nanotechnology in Cancer Carbon Nanotube X-ray Source ...................................................................................................................................... 52 Surface Enhanced Raman Spectrometry Gold-Based Nanoparticles for Colorectal Cancer Detection ............................ 53 Chemically Engineered Adenovirus Nanoparticles to Improve Immune Gene Therapy in Chronic Lymphocytic Leukemia ................................................................................................................................................................... 54 NANOTECHNOLOGY CHARACTERIZATION LABORATORY ............................................................................................................. 55 TECHNOLOGY TRANSFER AND COMMERCIALIZATION .................................................... 59 ANC INDUSTRIAL PARTNERSHIPS AND COMPANY PROFILES ...................................................................................................... 59 SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM .................................................................................................... 67 BIOINFORMATICS AND DATA SHARING ........................................................................... 71 CONNECTIVITY WITH CABIG® .................................................................................................................................................. 71 CANANOLAB ........................................................................................................................................................................... 71 Nanotechnology Data Sharing Standards ....................................................................................................................... 72 MEETINGS ......................................................................................................................... 73 ANNUAL MEETING OF THE AMERICAN ASSOCIATION OF CANCER RESEARCH ............................................................................... 73 ANNUAL ANC INVESTIGATORS MEETINGS ................................................................................................................................ 74 NCI STRATEGIC WORKSHOPS .................................................................................................................................................. 75 BEST PRACTICES IN NANOTECHNOLOGY